Clinical Scorecard: Efficacy Assessment of Romosozumab Versus Denosumab and Risedronate in Patients Starting Glucocorticoid Treatment
At a Glance
Category
Detail
Condition
Glucocorticoid-induced osteoporosis (GIOP)
Key Mechanisms
Wnt/β-catenin signaling pathway inhibition by sclerostin leading to impaired bone formation and increased bone resorption
Target Population
Patients with rheumatic diseases newly starting glucocorticoid therapy (prednisolone ≥15 mg/day) without prior osteoporosis treatment
Care Setting
University hospital outpatient setting with routine clinical follow-up
Key Highlights
Romosozumab (ROMO), a sclerostin inhibitor, significantly increased lumbar spine bone mineral density (BMD) by 8.6% at 12 months compared to denosumab (3.3%) and bisphosphonates (−0.4%) in glucocorticoid-treated patients.
ROMO demonstrated dual effects by slightly increasing bone formation markers and decreasing bone resorption markers, contrasting with reductions in bone formation markers seen with denosumab and bisphosphonates.
Current standard treatments for GIOP include bisphosphonates and denosumab; teriparatide is effective but less commonly used initially due to administration burden.
Guideline-Based Recommendations
Diagnosis
Assess bone mineral density (BMD) using dual-energy X-ray absorptiometry (DEXA) at lumbar spine, femoral neck, and total hip every 6 months after glucocorticoid initiation.
Evaluate bone turnover markers every 3 months to monitor bone formation and resorption.
Management
Initiate osteoporosis treatment in patients starting glucocorticoids ≥7.5 mg/day for at least 3 months, especially with risk factors per Japanese Society for Bone and Mineral Research criteria.
Romosozumab administered subcutaneously at 210 mg monthly for 12 months is effective in increasing BMD in GIOP patients.
Denosumab 60 mg subcutaneously every 6 months and weekly oral bisphosphonates (risedronate 17.5 mg) are alternative treatments.
Recommend concomitant active vitamin D3 supplementation, particularly in patients with low 25-hydroxyvitamin D levels (<20 ng/mL).
Monitoring & Follow-up
Regularly monitor BMD changes at 6 and 12 months to evaluate treatment efficacy.
Monitor serum calcium and bone turnover markers to adjust vitamin D and calcium supplementation.
Observe for adverse events and contraindications, especially cardiovascular history before romosozumab use.
Risks
Romosozumab contraindicated in patients with recent (within 1 year) cardiovascular or cerebrovascular events.
Potential for bone fragility and increased vertebral fracture risk early after glucocorticoid initiation necessitates prompt treatment.
Patient burden with teriparatide limits its initial use despite efficacy.
Patient & Prescribing Data
Patients with rheumatic diseases newly initiating high-dose glucocorticoid therapy without prior osteoporosis treatment
Romosozumab shows superior lumbar spine BMD improvement compared to denosumab and bisphosphonates over 12 months; bone formation markers are better preserved with romosozumab.
Clinical Best Practices
Start osteoporosis prophylaxis promptly in patients beginning glucocorticoids ≥7.5 mg/day for ≥3 months.
Consider romosozumab as a first-line option for GIOP patients without cardiovascular contraindications due to its dual anabolic and antiresorptive effects.
Use denosumab or bisphosphonates as alternatives when romosozumab is contraindicated or not feasible.
Supplement with active vitamin D3 and calcium as needed based on serum levels.
Monitor BMD and bone turnover markers regularly to guide therapy adjustments.
